Literature DB >> 9729005

Intellectual property, drug licensing, freedom of information, and public health.

I Roberts1, A L Po, I Chalmers.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9729005     DOI： 10.1016/S0140-6736(98)07600-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?

Authors:  W K Kraft; S A Waldman
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Ethics behind closed doors: do research ethics committees need secrecy?

Authors:  R Ashcroft; N Pfeffer
Journal:  BMJ       Date:  2001-05-26

Review 3.  Synthesising licensing data to assess drug safety.

Authors:  Klim McPherson; Elina Hemminki
Journal:  BMJ       Date:  2004-02-28

4.  An amnesty for unpublished trials. One year on, many trials are unregistered and the amnesty remains open.

Authors:  I Roberts
Journal:  BMJ       Date:  1998-09-19

5.  Guidelines for the clinical use of albumin: comparison of use in two Italian hospitals and a third hospital without guidelines.

Authors:  Antonietta Martelli; Paolo Strada; Ildefonso Cagliani; Giovanni Brambilla
Journal:  Curr Ther Res Clin Exp       Date:  2003-11

6.  Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis.

Authors:  S Holt; A Suder; M Weatherall; S Cheng; P Shirtcliffe; R Beasley
Journal:  BMJ       Date:  2001-08-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.